The week in health tech, explained in plain English.Get the free newsletter →
October 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Payers

CVS CEO: GLP-1 Economics 'Aren't There Yet' for Employers

By Healthcare Technology News ·

CVS Health CEO David Joyner is pouring cold water on the idea that employers should broadly cover GLP-1 weight-loss drugs at current prices. "Everybody intuitively believes these medications create long-term health benefits, but the evidence hasn't yet demonstrated that paying today's prices generates enough downstream savings," he told The Washington Post in a July 12 report. "The economics simply aren't there yet."

The remarks matter because CVS owns Caremark, one of the country's largest pharmacy benefit managers, which shapes what drugs employers and health plans cover. Drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound carry list prices above $1,000 a month, and demand has strained employer budgets. Many companies have restricted or dropped coverage as costs climbed faster than any demonstrated reduction in medical spending.

Joyner's skepticism reflects a broader industry standoff: intuitive belief in these drugs versus a lack of hard evidence that paying now yields savings later. Until pricing drops or long-term data firms up, expect payers to keep coverage tight.

Sources

More in Payers

Payers

Patients Are Taking Insurance Denials Straight to the C-Suite

Some patients are overturning insurance denials by emailing insurer CEOs directly, a workaround that exposes deeper flaws in the standard appeals process.

Why it matters: When patients must reach the CEO to get covered care approved, it signals the normal denial and appeals system is failing the people it should serve.

Payers

Academic Health Systems Are Underpricing Their Payer Contracts

ECG's managed care experts say academic health systems routinely undervalue their advanced services in payer contracts and must negotiate terms that reflect their true costs.

Why it matters: Academic health systems operate on thin margins, and payer contracts that ignore their higher costs threaten the research and safety-net care only they provide.

Payers

Why Insurers Want Agentic AI as Connective Tissue

Health insurers are looking to agentic AI to orchestrate their existing systems rather than buy more standalone tools, Healthcare Dive reports.

Why it matters: If agentic AI can connect fragmented payer systems, it could cut the administrative costs that make health insurance slow and expensive.